Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $80.57, reflecting a -0.57% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...